The_DT regulation_NN of_IN protein_NN synthesis_NN and_CC translation_NN factors_NNS by_IN CD3_NP and_CC CD28_NP in_IN human_JJ primary_JJ T_NN lymphocytes_NNS Abstract_NP |_SYM Background_NP |_SYM Activation_NN of_IN human_JJ resting_JJ T_NN lymphocytes_NNS results_NNS in_IN an_DT immediate_JJ increase_NN in_IN protein_NN synthesis_NN ._SENT The_DT increase_NN in_IN protein_NN synthesis_NN after_IN 16_CD --_: 24_CD h_NN has_VBZ been_VBN linked_VBN to_TO the_DT increased_VBN protein_NN levels_NNS of_IN translation_NN initiation_NN factors_NNS ._SENT However_RB ,_, the_DT regulation_NN of_IN protein_NN synthesis_NN during_IN the_DT early_JJ onset_NN of_IN T_NN cell_NN activation_NN has_VBZ not_RB been_VBN studied_VBN in_IN great_JJ detail_NN ._SENT We_PP studied_VBD the_DT regulation_NN of_IN protein_NN synthesis_NN after_IN 1_CD h_NN of_IN activation_NN using_VBG alphaCD3_JJ antibody_NN to_TO stimulate_VB the_DT T_NN cell_NN receptor_NN and_CC alphaCD28_JJ antibody_NN to_TO provide_VB the_DT co-stimulus_NN ._SENT Results_NNS |_SYM Activation_NN of_IN the_DT T_NN cells_NNS with_IN both_DT antibodies_NNS led_VBN to_TO a_DT sustained_JJ increase_NN in_IN the_DT rate_NN of_IN protein_NN synthesis_NN ._SENT The_DT activities_NNS and/or_CC phosphorylation_NN states_NNS of_IN several_JJ translation_NN factors_NNS were_VBD studied_VBN during_IN the_DT first_JJ hour_NN of_IN stimulation_NN with_IN alphaCD3_NN and_CC alphaCD28_NN to_TO explore_VB the_DT mechanism_NN underlying_VBG the_DT activation_NN of_IN protein_NN synthesis_NN ._SENT The_DT initial_JJ increase_NN in_IN protein_NN synthesis_NN was_VBD accompanied_VBN by_IN activation_NN of_IN the_DT guanine_NN nucleotide_NN exchange_NN factor_NN ,_, eukaryotic_JJ initiation_NN factor_NN (_( eIF_NN )_) 2B_JJ ,_, and_CC of_IN p70_JJ S6_NP kinase_NN and_CC by_IN dephosphorylation_NN of_IN eukaryotic_JJ elongation_NN factor_NN (_( eEF_NN )_) 2_CD ._SENT Similar_JJ signal_NN transduction_NN pathways_NNS ,_, as_RB assessed_VBD using_VBG signal_NN transduction_NN inhibitors_NNS ,_, are_VBP involved_VBN in_IN the_DT regulation_NN of_IN protein_NN synthesis_NN ,_, eIF2B_NN activity_NN and_CC p70_JJ S6_NP kinase_NN activity_NN ._SENT A_DT new_JJ finding_NN was_VBD that_IN the_DT p38_JJ MAPK_NP alpha/beta_NN pathway_NN was_VBD involved_VBN in_IN the_DT regulation_NN of_IN overall_JJ protein_NN synthesis_NN in_IN primary_JJ T_NN cells_NNS ._SENT Unexpectedly_RB ,_, no_DT changes_NNS were_VBD detected_VBN in_IN the_DT phosphorylation_NN state_NN of_IN the_DT cap-binding_JJ protein_NN eIF4E_NNS and_CC the_DT eIF4E-binding_NN protein_NN 4E-BP1_JJ ,_, or_CC the_DT formation_NN of_IN the_DT cap-binding_JJ complex_JJ eIF4F_NN ._SENT Conclusions_NNS |_SYM Both_DT eIF2B_NN and_CC p70_JJ S6_NP kinase_NN play_VBP important_JJ roles_NNS in_IN the_DT regulation_NN of_IN protein_NN synthesis_NN during_IN the_DT early_JJ onset_NN of_IN T_NN cell_NN activation_NN ._SENT The_DT initiation_NN of_IN translation_NN of_IN mRNAs_NNS is_VBZ an_DT important_JJ control_NN point_NN in_IN protein_NN synthesis_NN in_IN eukaryotes_NNS and_CC requires_VBZ a_DT set_NN of_IN initiation_NN factors_NNS (_( eIFs_NNS )_) ._SENT The_DT cap-binding_JJ protein_NN eIF4E_NN recognises_VBZ the_DT 5'cap-structure_NN of_IN the_DT mRNA_NN ,_, and_CC is_VBZ a_DT component_NN of_IN the_DT eIF4F_NN complex_NN consisting_VBG of_IN eIF4E_NN ,_, eIF4G_NN ,_, a_DT scaffolding_NN protein_NN ,_, and_CC eIF4A_NP ,_, an_DT RNA_NP helicase_NN ._SENT Any_DT secondary_JJ structure_NN in_IN the_DT 5'untranslated_JJ region_NN of_IN the_DT mRNA_NN is_VBZ thought_VBN to_TO be_VB unwound_VBN by_IN eIF4A_NN together_RB with_IN eIF4B_NN or_CC eIF4H_NN ._SENT The_DT 40S_JJ subunit_NN of_IN the_DT ribosome_NN binds_VBZ to_TO the_DT eIF4F_NN complex_NN through_IN an_DT association_NN between_IN eIF4G_NN and_CC eIF3_NN ,_, which_WDT interacts_VBZ directly_RB with_IN the_DT 40S_JJ ribosomal_JJ subunit_NN ._SENT The_DT preinitiation_NN complex_NN ,_, containing_VBG the_DT 40S_JJ ribosomal_JJ subunit_NN ,_, eIF4F_NN ,_, eIF4B_NN ,_, and_CC Met-tRNAi*eIF2*GTP_NP ,_, scans_VBZ the_DT 5'UTR_NN until_IN the_DT AUG_NP start_NN codon_NN is_VBZ located_VBN ._SENT The_DT subsequent_JJ hydrolysis_NN of_IN the_DT GTP_NP bound_VBN to_TO eIF2_NN is_VBZ promoted_VBN by_IN eIF5_NN ,_, after_IN which_WDT eIF2*GDP_NN leaves_VBZ the_DT ribosome_NN ._SENT The_DT 60S_JJ ribosomal_JJ subunit_NN can_MD then_RB join_VB and_CC the_DT 80S_JJ complex_NN is_VBZ formed_VBN ._SENT eIF2_NN in_IN the_DT GDP-bound_JJ state_NN is_VBZ inactive_JJ and_CC ,_, in_IN order_NN to_TO return_VB to_TO the_DT active_JJ form_NN again_RB ,_, the_DT GDP_NP is_VBZ exchanged_VBN for_IN GTP_NP in_IN a_DT step_NN promoted_VBN by_IN the_DT guanine_NN nucleotide_NN exchange_NN factor_NN eIF2B_NN ._SENT The_DT next_JJ stage_NN in_IN the_DT translation_NN process_NN ,_, the_DT elongation_NN step_NN ,_, can_MD be_VB regulated_VBN via_IN changes_NNS in_IN the_DT activity_NN of_IN eEF2_NN ._SENT Phosphorylation_NN of_IN eEF2_NN at_IN Thr56_NP results_NNS in_IN its_PP$ complete_JJ inactivation_NN ._SENT Human_JJ primary_JJ T-cells_NNS are_VBP metabolically_RB quiescent_JJ ,_, with_IN little_JJ ongoing_JJ DNA_NN ,_, RNA_NP or_CC protein_NN synthesis_NN ._SENT The_DT low_JJ protein_NN synthesis_NN rate_NN in_IN quiescent_JJ T_NN cells_NNS is_VBZ associated_VBN with_IN low_JJ levels_NNS of_IN initiation_NN factors_NNS in_IN these_DT cells_NNS ._SENT The_DT rate_NN of_IN protein_NN synthesis_NN increase_NN 2_CD --_: 4_CD fold_NN after_IN 4_CD h_NN of_IN mitogenic_JJ stimulation_NN ,_, and_CC it_PP has_VBZ been_VBN reported_VBN that_IN the_DT mRNA_NN and_CC protein_NN levels_NNS for_IN several_JJ translation_NN initiation_NN factors_NNS increased_VBN during_IN T_NN cell_NN activation_NN ._SENT The_DT mRNA_NN levels_NNS of_IN eIF4A_NN ,_, eIF2alpha_NP ,_, and_CC eIF4E_NNS increased_VBD rapidly_RB after_IN stimulation_NN ._SENT However_RB ,_, the_DT increase_NN in_IN the_DT levels_NNS of_IN the_DT corresponding_JJ protein_NN lagged_VBD significantly_RB behind_RB ._SENT It_PP is_VBZ therefore_RB likely_JJ that_IN increased_VBN levels_NNS of_IN translation_NN factors_NNS contribute_VBP to_TO the_DT pronounced_JJ stimulation_NN of_IN protein_NN synthesis_NN that_WDT occurs_VBZ during_IN T_NN cell_NN activation_NN at_IN later_JJR times_NNS ,_, while_IN modulation_NN of_IN the_DT activity_NN of_IN several_JJ translation_NN initiation_NN factors_VBZ e.g._FW by_IN phosphorylation_NN or_CC association_NN with_IN binding_JJ proteins_NNS is_VBZ important_JJ in_IN the_DT early_JJ phase_NN of_IN T_NN cell_NN activation_NN ._SENT Increased_VBN phosphorylation_NN of_IN eIF4E_NNS in_IN T_NN lymphocytes_NNS has_VBZ been_VBN reported_VBN under_IN several_JJ conditions_NNS ._SENT Activation_NN of_IN quiescent_JJ mature_JJ porcine_JJ peripheral_JJ blood_NN mononuclear_JJ cells_NNS with_IN phorbol_NN 12-myristate_JJ 13-acetate_JJ (_( PMA_NN )_) or_CC concanavalin_NP A_NP or_CC stimulation_NN of_IN human_JJ primary_JJ T_NN cells_NNS with_IN PHA_NP ,_, PMA_NN ,_, or_CC PMA_NN plus_CC ionomycin_NN caused_VBD a_DT rapid_JJ increase_NN in_IN the_DT phosphorylation_NN of_IN eIF4E_NNS ._SENT Similarly_RB ,_, stimulation_NN of_IN the_DT T_NN cell_NN receptor_NN in_IN the_DT human_JJ leukaemic_JJ T_NN cell_NN line_NN Jurkat_NP with_IN OKT-3_NP ,_, or_CC treatment_NN with_IN PMA_NN ,_, increased_VBD eIF4E_JJ phosphorylation_NN ,_, and_CC a_DT significant_JJ increase_NN in_IN the_DT amount_NN of_IN eIF4F_NN complexes_NNS was_VBD also_RB detected_VBN ._SENT The_DT activity_NN of_IN eIF4E_NNS can_MD also_RB be_VB modulated_VBN by_IN its_PP$ association_NN with_IN eIF4E-binding_NN proteins_NNS ,_, of_IN which_WDT 4E-BP1_JJ is_VBZ the_DT best-studied_JJ ._SENT Phosphorylation_NN of_IN 4E-BP1_JJ leads_NNS to_TO its_PP$ dissociation_NN from_IN eIF4E_NNS ,_, leaving_VBG eIF4E_NNS free_JJ to_TO bind_VB eIF4G_NN and_CC form_NN eIF4F_NN complexes_NNS ._SENT In_IN a_DT murine_JJ cytotoxic_JJ T_NN cell_NN line_NN ,_, interleukin-2_NN induced_VBD the_DT phosphorylation_NN of_IN 4E-BP1_JJ ._SENT 4E-BP1_JJ is_VBZ present_JJ in_IN human_JJ primary_JJ T_NN lymphocytes_NNS and_CC becomes_VBZ phosphorylated_JJ in_IN response_NN to_TO PMA_NN or_CC PMA_NN plus_CC ionomycin_NN ._SENT In_IN several_JJ cell_NN lines_NNS ,_, an_DT increase_NN in_IN eIF2B_NN activity_NN coincides_VBZ with_IN an_DT increase_NN in_IN protein_NN synthesis_NN ._SENT One_CD mechanism_NN to_TO regulate_VB the_DT activity_NN of_IN eIF2B_NN is_VBZ via_IN phosphorylation_NN of_IN its_PP$ epsilon-subunit_NN (_( eIF2Bepsilon_NN )_) by_IN GSK-3_NP ,_, which_WDT causes_VBZ a_DT decrease_NN in_IN eIF2B_NN activity_NN ._SENT Stimulation_NN of_IN T_NN cells_NNS with_IN PMA_NN plus_CC ionomycin_NN caused_VBD a_DT rapid_JJ rise_NN in_IN eIF2B_NN activity_NN ,_, which_WDT coincided_VBD with_IN inactivation_NN of_IN GSK-3_NP ,_, suggesting_VBG a_DT role_NN for_IN dephosphorylation_NN of_IN eIF2Bepsilon_NN ._SENT The_DT activity_NN of_IN eIF2B_NN can_MD also_RB be_VB modulated_VBN by_IN phosphorylation_NN of_IN the_DT alpha-subunit_NN of_IN eIF2_NN ._SENT eIF2_NN phosphorylated_JJ in_IN its_PP$ alpha-subunit_NN acts_NNS as_IN a_DT competitive_JJ inhibitor_NN of_IN eIF2B_NN ._SENT Stimulation_NN of_IN T_NN cells_NNS with_IN PHA_NP did_VBD not_RB cause_VB significant_JJ changes_NNS in_IN the_DT phosphorylation_NN state_NN of_IN eIF2alpha_NN ,_, excluding_VBG this_DT mechanism_NN of_IN regulation_NN under_IN this_DT condition_NN ._SENT In_IN this_DT study_NN we_PP used_VBD the_DT antibodies_NNS ,_, alphaCD3_NN and_CC alphaCD28_NN ,_, to_TO activate_VB resting_VBG human_JJ primary_JJ T_NN lymphocytes_NNS ._SENT Engagement_NN of_IN alphaCD3_NN activates_VBZ the_DT T_NN cell_NN receptor_NN ,_, while_IN cross-linking_NN of_IN alphaCD28_NN with_IN the_DT B7_JJ receptor_NN will_MD supply_VB a_DT co-stimulatory_JJ signal_NN ,_, which_WDT is_VBZ required_VBN for_IN full_JJ activation_NN of_IN a_DT resting_JJ T_NN cell_NN ._SENT We_PP have_VBP studied_VBN the_DT effects_NNS of_IN T_NN cell_NN activation_NN on_IN protein_NN synthesis_NN and_CC on_IN the_DT activities_NNS and/or_CC phosphorylation_NN states_NNS of_IN several_JJ translation_NN initiation_NN factors_NNS ._SENT Furthermore_RB ,_, the_DT signalling_VBG pathways_NNS involved_VBN in_IN these_DT changes_NNS have_VBP been_VBN investigated_VBN ._SENT Activation_NN of_IN primary_JJ T_NN cells_NNS with_IN a_DT physiological_JJ stimulus_NN increased_VBD protein_NN synthesis_NN |_SYM We_PP activated_VBD T_NN cells_NNS with_IN the_DT antibodies_NNS ,_, alphaCD3_NN and_CC alphaCD28_NN ,_, for_IN up_RB to_TO 24h_JJ and_CC measured_JJ protein_NN synthesis_NN and_CC the_DT activation_NN of_IN several_JJ signalling_VBG pathways_NNS that_WDT are_VBP important_JJ for_IN the_DT regulation_NN of_IN translation_NN factors_NNS and_CC that_WDT have_VBP been_VBN shown_VBN to_TO increase_VB after_IN activation_NN of_IN T_NN cells_NNS ._SENT Figure_NP 1_CD |_SYM Activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN ._SENT Activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28.A_NN ._SENT Primary_JJ T_NN lymphocytes_NNS were_VBD activated_VBN with_IN both_DT alphaCD3_NN and_CC alphaCD28_NN for_IN 4_CD ,_, 8_CD ,_, 16_CD or_CC 24_CD h_NN and_CC for_IN the_DT last_JJ 45_CD min_NN 10_CD muCi/ml_NN of_IN [_SYM 35S]-labelled_JJ methionine_NN was_VBD present_JJ ._SENT The_DT experiment_NN was_VBD performed_VBN in_IN duplicate_NN ._SENT Incorporation_NN of_IN [_SYM 35S]-labelled_JJ methionine_NN into_IN equal_JJ amounts_NNS of_IN protein_NN was_VBD measured_VBN ._SENT Protein_NN synthesis_NN in_IN control_NN cells_NNS was_VBD set_VBN at_IN 100_CD %_NN ._SENT Methionine_NN incorporation_NN ranged_VBD between_IN 1000_CD and_CC 2000_CD cpm_NN per_IN 50_CD mug_NN of_IN protein_NN ._SENT (_( control_VB cells_NNS at_IN t_NN =_SYM 0_CD h_NN and_CC t_NN =_SYM 24_CD h_NN are_VBP not_RB significantly_RB different_JJ ,_, n_NN =_SYM 3_CD )_) ._SENT B._NP T_NN cells_NNS were_VBD activated_VBN by_IN alphaCD3_NN and_CC alphaCD28_NN or_CC with_IN PMA_NN ._SENT Cells_NNS were_VBD activated_VBN for_IN 30_CD min_NN ,_, harvested_VBN and_CC 50_CD --_: 80_CD mug_NN of_IN lysate_NNS was_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT Antibodies_NNS that_WDT recognize_VBP the_DT phosphorylated_JJ form_NN of_IN either_DT ERK_NP (_( pp42_NN )_) or_CC p38_NP MAPK_NP (_( pp38_NN )_) were_VBD used_VBN ._SENT Even_RB loading_VBG of_IN the_DT gel_NN was_VBD verified_VBN using_VBG anti-ERK2_NN (_( p42_NN )_) ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD sets_NNS of_IN experiments_NNS ._SENT C._NP PKB_NP activity_NN was_VBD measured_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP (_( p_NN <0.05,_n=4). 16_CD h_NN )_) following_VBG T_NN cell_NN activation_NN and_CC probably_RB contribute_VB to_TO the_DT increase_NN in_IN protein_NN synthesis_NN ._SENT To_TO examine_VB whether_IN activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN also_RB affected_VBN initiation_NN factor_NN levels_NNS ,_, the_DT amounts_NNS of_IN the_DT cap-binding_JJ protein_NN ,_, eIF4E_NNS ,_, and_CC of_IN the_DT catalytic_JJ subunit_NN of_IN the_DT eIF2B_NN complex_NN ,_, eIF2Bepsilon_NN ,_, were_VBD assessed_VBN at_IN different_JJ time_NN points_NNS ._SENT The_DT amounts_NNS of_IN eIF4E_NN and_CC eIF2Bepsilon_NN protein_NN each_DT remained_VBN constant_JJ during_IN the_DT first_JJ 6_CD h._JJ Figure_NP 2_CD |_SYM The_DT amount_NN of_IN eIF4E_NN and_CC eIF2Bepsilon_NN protein_NN did_VBD not_RB change_VB in_IN the_DT early_JJ phase_NN of_IN T_NN cell_NN activation_NN ._SENT The_DT amount_NN of_IN eIF4E_NN and_CC eIF2Bepsilon_NN protein_NN did_VBD not_RB change_VB in_IN the_DT early_JJ phase_NN of_IN T_NN cell_NN activation_NN ._SENT T_NN cells_NNS were_VBD activated_VBN with_IN alphaCD3_NN and_CC alphaCD28_NN for_IN the_DT indicated_JJ times_NNS ._SENT In_IN each_DT case_NN ,_, 600_CD mug_NN of_IN protein_NN was_VBD used_VBN for_IN an_DT m7GTP_NP Sepharose_NP pull_VB down_RP to_TO detect_VB the_DT amount_NN of_IN eIF4E_NNS or_CC used_VBN in_IN an_DT immunoprecipitation_NN reaction_NN with_IN alphaeIF2Bepsilon_NN coupled_VBN to_TO protein_NN G_NN to_TO detect_VB eIF2Bepsilon_NN ._SENT The_DT pull_NN downs_NNS were_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT The_DT experiment_NN was_VBD performed_VBN in_IN duplicate_NN ._SENT In_IN this_DT study_NN ,_, we_PP have_VBP focused_VBN on_IN the_DT mechanisms_NNS underlying_VBG the_DT initial_JJ response_NN after_IN activation_NN of_IN primary_JJ T_NN cells_NNS by_IN alphaCD3_NN and_CC alphaCD28_NN and_CC the_DT concomitant_JJ increase_NN in_IN protein_NN synthesis_NN ._SENT Since_IN the_DT levels_NNS of_IN initiation_NN factor_NN proteins_NNS did_VBD not_RB change_VB in_IN this_DT early_JJ phase_NN of_IN T_NN cell_NN activation_NN ,_, we_PP considered_VBD the_DT possibility_NN that_IN changes_NNS in_IN the_DT phosphorylation_NN state_NN and/or_CC activities_NNS of_IN several_JJ translation_NN factors_NNS were_VBD involved_VBN in_IN the_DT initial_JJ activation_NN of_IN protein_NN synthesis_NN in_IN T_NN cells_NNS ._SENT Protein_NN synthesis_NN is_VBZ regulated_VBN via_IN multiple_JJ signalling_VBG pathways_NNS |_SYM Primary_JJ T_NN lymphocytes_NNS were_VBD activated_VBN with_IN alphaCD3_NN and_CC alphaCD28_NN ,_, and_CC after_IN 1_CD h_NN of_IN activation_NN ,_, protein_NN synthesis_NN was_VBD increased_VBN 1.2_CD fold_NN ._SENT To_TO study_VB the_DT signalling_VBG events_NNS involved_VBN in_IN this_DT increase_NN in_IN protein_NN synthesis_NN ,_, we_PP performed_VBD the_DT experiment_NN in_IN the_DT presence_NN of_IN different_JJ specific_JJ signal_NN transduction_NN pathway_NN inhibitors_NNS ._SENT The_DT increase_NN in_IN overall_JJ protein_NN synthesis_NN was_VBD consistently_RB blocked_VBN by_IN each_DT of_IN the_DT signal_NN transduction_NN inhibitors_NNS used_VBN ,_, i.e._FW the_DT PI_NP 3-kinase_JJ inhibitor_NN wortmannin_NN ,_, the_DT mTOR_NN inhibitor_NN rapamycin_NN ,_, the_DT p38_JJ MAPKalpha/beta_NP inhibitors_NNS SB203580_NP and_CC SB202190_NP ,_, and_CC the_DT MEK_NP inhibitor_NN PD98059_NP ._SENT It_PP appears_VBZ that_IN the_DT immediate_JJ activation_NN of_IN protein_NN synthesis_NN in_IN T_NN cells_NNS involves_VBZ interplay_NN between_IN several_JJ signalling_VBG pathways_NNS ._SENT Figure_NP 3_CD |_SYM The_DT increase_NN in_IN protein_NN synthesis_NN requires_VBZ signalling_VBG via_IN several_JJ pathways_NNS ._SENT The_DT increase_NN in_IN protein_NN synthesis_NN requires_VBZ signalling_VBG via_IN several_JJ pathways_NNS ._SENT T_NN cells_NNS were_VBD preincubated_VBN with_IN wortmannin_NP (_( W_NP ,_, 100_CD nM_NN )_) ,_, rapamycin_NP (_( R_NP ,_, 100_CD nM_NN )_) ,_, SB203580_NP (_( 10_CD muM_NN )_) ,_, SB202190_NP (_( 10_CD muM_NN )_) or_CC PD98059_NP (_( PD_NP ,_, 50_CD muM_NN )_) for_IN 30_CD min_NN before_IN activation_NN with_IN both_DT alphaCD3_NN and_CC alphaCD28_NN for_IN 1_CD h_NN or_CC the_DT cells_NNS were_VBD treated_VBN with_IN PMA_NN (_( 1_CD muM_NN )_) for_IN 1_CD h._NN For_IN the_DT last_JJ 30_CD min_NN of_IN activation_NN 10_CD muCi/ml_NN [_SYM 35S]-labelled_JJ methionine_NN was_VBD present_JJ ._SENT The_DT experiment_NN was_VBD performed_VBN in_IN duplicate_NN ._SENT Protein_NN synthesis_NN in_IN control_NN cells_NNS was_VBD set_VBN at_IN 100_CD %_NN ._SENT Methionine_NN incorporation_NN ranged_VBD between_IN 600_CD and_CC 1500_CD cpm_NN per_IN 50_CD mug_NN of_IN protein_NN ._SENT Incorporation_NN of_IN [_SYM 35S]-labelled_JJ methionine_NN into_IN equal_JJ amounts_NNS of_IN protein_NN was_VBD measured_VBN using_VBG hot_JJ TCA_NN precipitation_NN (_( p<0.05_NN for_IN the_DT alphaCD3/28_NN and_CC PMA_NN treated_VBN samples_NNS ;_: all_DT other_JJ samples_NNS are_VBP not_RB significantly_RB different_JJ from_IN the_DT control_NN ,_, n=6_NP )_) ._SENT Stimulation_NN of_IN T_NN cells_NNS with_IN the_DT more_RBR potent_JJ stimulus_NN PMA_NN for_IN 1_CD h_NN led_VBN to_TO a_DT substantially_RB larger_JJR increase_NN in_IN protein_NN synthesis_NN (_( 1.8_CD fold_NN )_) compared_VBN to_TO activation_NN with_IN alphaCD3_NN and_CC alphaCD28_NN ._SENT Phosphorylation_NN of_IN eIF4E_NN ,_, eIF4F_NN complex_JJ formation_NN and_CC 4E-BP1_JJ phosphorylation_NN remain_VBP unchanged_JJ after_IN T_NN cell_NN activation_NN |_SYM Phosphorylation_NN of_IN the_DT cap-binding_JJ protein_NN eIF4E_NNS can_MD be_VB regulated_VBN via_IN the_DT ERK_NP and_CC p38_NP MAPKalpha/betapathways_NP ,_, two_CD pathways_NNS that_WDT appear_VBP to_TO be_VB important_JJ for_IN the_DT regulation_NN of_IN protein_NN synthesis_NN in_IN T_NN cells_NNS ._SENT Furthermore_RB ,_, the_DT phosphorylation_NN of_IN eIF4E_NNS has_VBZ been_VBN reported_VBN to_TO be_VB increased_VBN in_IN response_NN to_TO several_JJ different_JJ treatments_NNS of_IN primary_JJ T_NN lymphocytes_NNS or_CC the_DT Jurkat_NP T_NN cell_NN line_NN ._SENT However_RB ,_, activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN for_IN up_IN to_TO 60_CD min_NN did_VBD not_RB cause_VB a_DT significant_JJ change_NN in_IN the_DT phosphorylation_NN state_NN of_IN eIF4E_NNS ._SENT Stimulation_NN of_IN T_NN cells_NNS with_IN either_DT alphaCD3_NN or_CC alphaCD28_NN alone_RB was_VBD also_RB insufficient_JJ to_TO change_VB the_DT phosphorylation_NN state_NN of_IN eIF4E_NN (_( data_NNS not_RB shown_VBN )_) ._SENT We_PP did_VBD detect_VB a_DT marked_JJ change_NN in_IN phosphorylation_NN of_IN eIF4E_NNS after_IN 30_CD min_NN of_IN PMA_NN treatment_NN ,_, indicating_VBG that_IN the_DT cells_NNS respond_VB to_TO this_DT stimulus_NN ._SENT In_IN addition_NN ,_, treatment_NN of_IN the_DT Jurkat_NP T_NN cell_NN line_NN with_IN alphaCD3_NN and_CC alphaCD28_NN caused_VBD phosphorylation_NN of_IN eIF4E_NNS that_WDT was_VBD already_RB detectable_JJ after_IN 30_CD min_NN ,_, demonstrating_VBG the_DT effectiveness_NN of_IN the_DT antibodies_NNS (_( alphaCD3_NN and_CC alphaCD28_NN )_) used_VBN ._SENT Figure_NP 4_CD |_SYM Regulation_NN of_IN eIF4E_JJ phosphorylation_NN and_CC eIF4F_NN formation_NN ._SENT Regulation_NN of_IN eIF4E_JJ phosphorylation_NN and_CC eIF4F_NN formation.A_NN ._SENT Jurkat_NP T_NN cells_NNS were_VBD activated_VBN for_IN 30_CD or_CC 60_CD min_NN by_IN both_DT alphaCD3_NN and_CC alphaCD28_NN ._SENT The_DT primary_JJ T_NN lymphocytes_NNS were_VBD activated_VBN for_IN the_DT indicated_JJ times_NNS with_IN both_DT alphaCD3_NN and_CC alphaCD28_NN or_CC with_IN PMA_NN ._SENT eIF4E_NNS was_VBD purified_VBN using_VBG m7GTP_NP Sepharose_NP ,_, analyzed_VBD on_IN a_DT one-dimensional_JJ iso-electric_JJ focusing_VBG gel_NN and_CC detected_VBN by_IN Western_NP blotting_VBG ._SENT 4E_JJ and_CC 4E-P_JJ indicate_VBP unphosphorylated_JJ and_CC phosphorylated_JJ eIF4E_NNS respectively_RB ._SENT B._NP 100_CD mug_NN of_IN total_JJ cell_NN lysate_NNS from_IN primary_JJ T_NN cells_NNS treated_VBN for_IN 1_CD h_NN with_IN alphaCD3_NN and_CC alphaCD28_NN or_CC PMA_NN was_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG to_TO detect_VB 4E-BP1_JJ ._SENT (_( -_: )_) indicates_VBZ untreated_JJ cells_NNS ._SENT The_DT lane_NN with_IN 4E-BP1_JJ from_IN HeLa_NP cell_NN extract_NN was_VBD obtained_VBN from_IN a_DT shorter_JJR exposure_NN from_IN the_DT same_JJ blot_NN ._SENT C._NP Formation_NP of_IN eIF4F_NN was_VBD analyzed_VBN after_IN 60_CD min_NN activation_NN of_IN primary_JJ T_NN cells_NNS with_IN either_DT alphaCD3_NN ,_, alphaCD28_NN or_CC both_DT ._SENT eIF4E_NNS was_VBD purified_VBN as_IN described_VBN above_IN and_CC its_PP$ association_NN with_IN eIF4G_NN was_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT An_DT eIF4E_NN blot_NN was_VBD used_VBN to_TO verify_VB equal_JJ loading_NN of_IN all_DT lanes_NNS ._SENT Similar_JJ results_NNS for_IN eIF4E_NN ,_, eIF4G_NN and_CC 4E-BP1_JJ were_VBD obtained_VBN in_IN three_CD independent_JJ experiments_NNS ._SENT An_DT important_JJ way_NN of_IN regulating_VBG eIF4F_NN assembly_NN is_VBZ through_IN eIF4E-binding_NN proteins_NNS such_JJ as_IN 4E-BP1_JJ ._SENT Phosphorylation_NN of_IN 4E-BP1_JJ leads_NNS to_TO its_PP$ release_NN from_IN eIF4E_NNS ,_, allowing_VBG the_DT latter_JJ protein_NN to_TO bind_VB eIF4G_NN ._SENT The_DT phosphorylation_NN of_IN 4E-BP1_JJ can_MD be_VB detected_VBN by_IN virtue_NN of_IN a_DT reduction_NN in_IN its_PP$ mobility_NN upon_IN SDS-PAGE_NP ._SENT As_IN a_DT control_NN to_TO demonstrate_VB that_IN different_JJ forms_NNS of_IN human_JJ 4E-BP1_JJ can_MD be_VB resolved_VBN on_IN our_PP$ gel_NN system_NN ,_, we_PP used_VBD HeLa_NP cell_NN extract_NN and_CC in_IN this_DT case_NN three_CD separate_JJ bands_NNS (_( alpha_NN ,_, beta_NN and_CC gamma_NN )_) were_VBD indeed_RB detected_VBN ,_, indicative_JJ of_IN differently_RB phosphorylated_JJ forms_NNS ._SENT In_IN resting_JJ T-cells_NNS ,_, 4E-BP1_JJ was_VBD mainly_RB present_JJ in_IN the_DT unphosphorylated_JJ form_NN (_( alpha-form_NN )_) as_RB reported_VBD before_RB ._SENT We_PP were_VBD unable_JJ to_TO detect_VB any_DT changes_NNS in_IN mobility_NN of_IN 4E-BP1_JJ ,_, and_CC therefore_RB its_PP$ phosphorylation_NN after_IN stimulation_NN of_IN the_DT cells_NNS with_IN alphaCD3_NN plus_CC alphaCD28_NN or_CC PMA_NN ._SENT Formation_NN of_IN eIF4F_NN complexes_NNS was_VBD studied_VBN by_IN purification_NN of_IN eIF4E_NNS on_IN m7GTP-Sepharose_NN followed_VBN by_IN a_DT Western_JJ blot_NN to_TO detect_VB associated_JJ eIF4G_NN ._SENT In_IN resting_JJ T_NN cells_NNS ,_, eIF4F_NN complexes_NNS are_VBP already_RB present_JJ ,_, and_CC after_IN 1h_NP of_IN activation_NN with_IN alphaCD3_NN ,_, alphaCD28_NN ,_, or_CC both_DT antibodies_NNS ,_, the_DT amount_NN of_IN eIF4G_NN bound_VBN to_TO eIF4E_NNS remained_VBD unchanged_JJ ._SENT Similar_JJ results_NNS were_VBD obtained_VBN after_IN 30_CD min_NN of_IN activation_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Surprisingly_RB ,_, no_DT 4E-BP1_JJ associated_VBN with_IN eIF4E_NNS was_VBD detected_VBN ,_, even_RB though_IN up_IN to_TO 2_CD mg_NN of_IN T_NN cell_NN extract_NN was_VBD used_VBN in_IN a_DT m7GTP_NP Sepharose_NP pull_VBP down_RB (_( data_NNS not_RB shown_VBN )_) ._SENT This_DT could_MD be_VB due_JJ to_TO low_JJ amounts_NNS of_IN 4E-BP1_JJ protein_NN present_NN in_IN resting_VBG T_NN cells_NNS ._SENT These_DT data_NNS indicate_VBP that_IN increased_VBN formation_NN of_IN eIF4F_NN complexes_NNS is_VBZ not_RB required_VBN for_IN the_DT activation_NN of_IN protein_NN synthesis_NN in_IN the_DT early_JJ phase_NN of_IN T_NN cell_NN activation_NN ._SENT Regulation_NN of_IN eIF2B_NN activity_NN after_IN activation_NN of_IN T_NN cells_NNS |_SYM In_IN several_JJ cell_NN types_NNS ,_, an_DT increase_NN in_IN overall_JJ protein_NN synthesis_NN coincides_VBZ with_IN an_DT increase_NN in_IN eIF2B_NN activity_NN ._SENT We_PP therefore_RB examined_VBD the_DT activity_NN of_IN eIF2B_NN after_IN activation_NN of_IN primary_JJ T_NN cells_NNS ._SENT After_IN 1_CD h_NN of_IN activation_NN with_IN alphaCD3_NN and_CC alphaCD28_NN ,_, the_DT activity_NN of_IN eIF2B_NN increased_VBD 2.2_CD fold_NN ._SENT The_DT increase_NN in_IN eIF2B_NN activity_NN was_VBD not_RB caused_VBN by_IN a_DT change_NN in_IN the_DT phosphorylation_NN state_NN of_IN the_DT alpha-subunit_NN of_IN eIF2_NN or_CC by_IN an_DT increase_NN in_IN the_DT amount_NN of_IN eIF2Bepsilon_NN protein_NN (_( Figs._NP and_CC and_NP )_) ._SENT Immunoprecipitation_NN of_IN different_JJ amounts_NNS of_IN T_NN cell_NN extracts_VBZ showed_VBD that_IN the_DT eIF2Bepsilon_NN antibody_NN was_VBD able_JJ to_TO detect_VB different_JJ levels_NNS of_IN protein_NN in_IN the_DT immunoprecipitations_NNS within_IN the_DT same_JJ range_NN used_VBN in_IN Fig._NN (_( bottom_JJ panel_NN )_) ._SENT Taken_VBN these_DT results_NNS together_RB it_PP suggested_VBD that_IN eIF2B_NN was_VBD regulated_VBN directly_RB ,_, e.g._FW via_IN phosphorylation_NN ._SENT To_TO study_VB which_WDT signal_VBP transduction_NN pathways_NNS are_VBP involved_VBN in_IN the_DT regulation_NN of_IN the_DT activity_NN of_IN eIF2B_NN ,_, the_DT cells_NNS were_VBD activated_VBN in_IN the_DT presence_NN of_IN specific_JJ signal_NN transduction_NN pathway_NN inhibitors_NNS and_CC eIF2B_NN activity_NN was_VBD measured_VBN ._SENT The_DT basal_JJ activity_NN of_IN eIF2B_NN was_VBD slightly_RB affected_VBN in_IN the_DT presence_NN of_IN the_DT PI_NP 3-kinase_JJ inhibitor_NN wortmannin_NN ,_, the_DT mTOR_NN inhibitor_NN rapamycin_NN ,_, and_CC the_DT p38_JJ MAPKalpha/beta_NP inhibitor_NN SB203580_NP ,_, however_RB the_DT alphaCD3_NN plus_CC alphaCD28-induced_JJ increase_NN in_IN eIF2B_NN activity_NN was_VBD completely_RB blocked_VBN in_IN the_DT presence_NN of_IN each_DT inhibitor_NN ._SENT The_DT MEK_NP inhibitor_NN PD98059_NP did_VBD not_RB affect_VB the_DT basal_JJ eIF2B_NN activity_NN and_CC was_VBD also_RB able_JJ to_TO inhibit_VB the_DT alphaCD3_NN and_CC alphaCD28-induced_JJ increase_NN in_IN eIF2B_NN activity_NN ,_, showing_VBG that_IN all_PDT these_DT signalling_VBG pathways_NNS are_VBP required_VBN to_TO mediate_VB the_DT activation_NN of_IN eIF2B_NN ._SENT Figure_NP 5_CD |_SYM Regulation_NN of_IN eIF2B_NN activity_NN ._SENT Regulation_NN of_IN eIF2B_NN activity.A_NN ._SENT T_NN cells_NNS were_VBD preincubated_VBN with_IN wortmannin_NP (_( W_NP ,_, 100_CD nM_NN )_) ,_, rapamycin_NP (_( R_NP ,_, 100_CD nM_NN )_) ,_, SB203580_NP (_( SB_NP ,_, 10_CD muM_NN )_) ,_, or_CC PD98059_NP (_( PD_NP ,_, 50muM_NP )_) for_IN 30_CD min_NN and_CC left_VBD untreated_JJ (_( white_JJ bar_NN )_) or_CC the_DT cells_NNS were_VBD activated_VBN with_IN both_DT alphaCD3_NN and_CC alphaCD28_JJ (_( black_JJ bar_NN )_) for_IN 1_CD h._JJ Simultaneously_NP cells_NNS were_VBD activated_VBN with_IN PMA_NN (_( hatched_VBN bar_NN )_) for_IN 1_CD h._NNS An_DT eIF2B_NN assay_NN was_VBD performed_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Bars_NNS marked_VBD with_IN *_SYM are_VBP significantly_RB different_JJ from_IN the_DT untreated_JJ cells_NNS (_( p<0.05_NP ,_, n=5_NP )_) ._SENT B._NP Cell_NP lysates_VBZ from_IN resting_VBG and_CC stimulated_VBN cells_NNS (_( 1_CD h_NN alphaCD3_NN and_CC alphaCD28_NN )_) were_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG to_TO detect_VB phosphorylated_JJ eIF2alpha_NN ._SENT eIF2B_NN was_VBD immunoprecipitated_VBN from_IN 400_CD mug_NN of_IN lysate_NNS using_VBG alphaeIF2Bepsilon_NN and_CC the_DT amount_NN of_IN protein_NN was_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD experiments_NNS C._NP To_TO test_VB the_DT sensitivity_NN of_IN the_DT eIF2Bepsilon_NN antibody_NN different_JJ amounts_NNS of_IN T_NN cell_NN extracts_VBZ (_( as_RB indicated_VBN )_) were_VBD immunoprecipitated_VBN with_IN alphaeIF2Bepsilon_NN and_CC analyzed_VBD by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN two_CD experiments_NNS ._SENT D._NP T_NN cells_NNS were_VBD left_VBN untreated_JJ (_( white_JJ bar_NN )_) or_CC the_DT cells_NNS were_VBD activated_VBN with_IN both_DT alphaCD3_NN and_CC alphaCD28_JJ (_( black_JJ bar_NN )_) or_CC PMA_NN (_( grey_JJ bar_NN )_) for_IN 1_CD h._NP GSK-3alpha_NP and_CC beta_NN were_VBD immunoprecipitated_VBN together_RB from_IN 400_CD mug_NN of_IN lysate_NNS and_CC a_DT kinase_NN assay_NN was_VBD performed_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP (_( p<0.05_NP ,_, n=4_NP )_) ._SENT E._NP eIF2Bepsilon_NP was_VBD immunoprecipitated_VBN from_IN 400_CD mug_NN of_IN lysate_NNS from_IN resting_VBG and_CC stimulated_VBN cells_NNS (_( 1_CD h_NN alphaCD3_NN and_CC alphaCD28_NN )_) and_CC the_DT total_JJ amount_NN of_IN eIF2Bepsilon_NN and_CC the_DT phosphorylation_NN state_NN of_IN Ser540_NP were_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN two_CD experiments_NNS ._SENT Activation_NN of_IN eIF2B_NN after_IN stimulation_NN of_IN the_DT cells_NNS with_IN PMA_NN was_VBD about_RB 2_CD fold_NN higher_JJR than_IN after_IN stimulation_NN with_IN the_DT antibodies_NNS ._SENT An_DT increase_NN in_IN eIF2B_NN activity_NN after_IN stimulation_NN of_IN primary_JJ T-cells_NNS with_IN PMA/ionomycin_NP has_VBZ been_VBN reported_VBN before_RB ._SENT It_PP has_VBZ been_VBN suggested_VBN that_IN GSK-3_NP may_MD be_VB an_DT important_JJ regulator_NN of_IN eIF2B_NN activity_NN ,_, i.e._FW in_IN response_NN to_TO insulin_NN and_CC during_IN cell_NN survival_NN ._SENT Phosphorylation_NN of_IN eIF2Bepsilon_NN by_IN GSK-3_NP inhibits_VBZ the_DT activity_NN of_IN the_DT eIF2B_NN complex_NN ._SENT GSK-3_JJ activity_NN is_VBZ decreased_VBN only_RB by_IN a_DT small_JJ extent_NN (_( 15_CD %_NN )_) after_IN T_NN cell_NN activation_NN with_IN alphaCD3_NN and_CC alphaCD28_NN ._SENT In_IN contrast_NN ,_, PMA_NN treatment_NN reduced_VBN GSK-3_NP activity_NN by_IN about_RB 50_CD %_NN ,_, which_WDT is_VBZ similar_JJ to_TO previously_RB reported_VBN data_NNS ._SENT GSK-3_NP phosphorylates_NNS eIF2Bepsilon_NN on_IN Ser540_NP ._SENT Therefore_RB ,_, we_PP analyzed_VBD the_DT phosphorylation_NN state_NN of_IN this_DT site_NN using_VBG a_DT phospho-specific_JJ antibody_NN ._SENT We_PP were_VBD unable_JJ to_TO detect_VB any_DT change_NN in_IN the_DT phosphorylation_NN of_IN this_DT site_NN in_IN response_NN to_TO alphaCD3_NN and_CC alphaCD28_NN ,_, excluding_VBG a_DT role_NN for_IN GSK-3_NP in_IN the_DT regulation_NN of_IN eIF2B_NN activity_NN in_IN T_NN cells_NNS under_IN these_DT conditions_NNS ._SENT Dephosphorylation_NN of_IN eEF2_NP |_SYM Elongation_NN factor_NN 2_CD (_( eEF2_NN )_) plays_VBZ an_DT important_JJ role_NN in_IN the_DT regulation_NN of_IN the_DT rate_NN of_IN elongation_NN ,_, and_CC therefore_RB in_IN the_DT regulation_NN of_IN the_DT rate_NN of_IN overall_JJ protein_NN synthesis_NN ._SENT Phosphorylation_NN of_IN eEF2_NN causes_VBZ its_PP$ inactivation_NN ._SENT Phosphorylation_NN of_IN eEF2_NN was_VBD rapidly_RB but_CC only_RB transiently_RB decreased_VBN after_IN activation_NN of_IN the_DT primary_JJ T_NN lymphocytes_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN ._SENT Within_IN 3_CD min_NN ,_, maximum_JJ dephosphorylation_NN was_VBD reached_VBN and_CC the_DT phosphorylation_NN level_NN returned_VBD to_TO a_DT level_NN similar_JJ to_TO that_DT of_IN resting_JJ T_NN cells_NNS by_IN 10_CD min_NN ._SENT Given_VBN the_DT transient_JJ nature_NN of_IN these_DT changes_NNS ,_, it_PP is_VBZ unlikely_JJ that_IN regulation_NN of_IN eEF2_NN plays_VBZ a_DT role_NN in_IN the_DT sustained_JJ increase_NN in_IN the_DT rate_NN of_IN protein_NN synthesis_NN after_IN activation_NN of_IN T_NN cells_NNS ._SENT However_RB ,_, dephosphorylation_NN of_IN eEF2_NN could_MD play_VB a_DT role_NN very_RB early_RB in_IN T_NN cell_NN activation_NN ._SENT Figure_NP 6_CD |_SYM Dephosphorylation_NN of_IN eEF2_NN after_IN T_NN cell_NN activation_NN ._SENT Dephosphorylation_NN of_IN eEF2_NN after_IN T_NN cell_NN activation_NN ._SENT T_NN cells_NNS were_VBD activated_VBN with_IN alphaCD3_NN and_CC alphaCD28_NN for_IN the_DT indicated_JJ times_NNS ._SENT 80_CD mug_NN of_IN protein_NN was_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT Phosphorylation_NN of_IN eEF2_NN was_VBD detected_VBN using_VBG a_DT phospho-specific_JJ antibody_NN (_( eEF2-P_NN )_) ._SENT ERK2_NP was_VBD detected_VBN as_IN a_DT loading_NN control_NN ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD experiments_NNS ._SENT Regulation_NN of_IN p70_JJ S6_NP kinase_NN upon_IN T_NN cell_NN activation_NN |_SYM Activation_NN of_IN p70_JJ S6_NP kinase_NN and_CC phosphorylation_NN of_IN the_DT ribosomal_JJ protein_NN S6_NP ,_, an_DT in_IN vivo_JJ substrate_NN of_IN p70_JJ S6_NP kinase_NN ,_, coincide_VB with_IN increased_VBN translation_NN of_IN specific_JJ mRNAs_NNS ,_, namely_RB the_DT 5'TOP_JJ mRNAs_NNS ._SENT However_RB ,_, a_DT recent_JJ report_NN has_VBZ questioned_VBN the_DT role_NN of_IN p70_JJ S6_NP kinase_NN in_IN 5'TOP_JJ messenger_NN translation_NN ._SENT We_PP studied_VBD the_DT effect_NN of_IN activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN plus_CC alphaCD28_NN on_IN these_DT proteins_NNS ._SENT The_DT activity_NN of_IN p70_JJ S6_NP kinase_NN was_VBD increased_VBN about_IN 1.5_CD fold_NN after_IN 60_CD min_NN ,_, and_CC the_DT increase_NN in_IN p70_JJ S6_NP kinase_NN activity_NN was_VBD blocked_VBN by_IN each_DT of_IN the_DT signal_NN transduction_NN inhibitors_NNS used_VBN ,_, i.e._FW wortmannin_NN ,_, PD98059_NP ,_, SB203580_NP ,_, and_CC rapamycin_NN ._SENT Similar_JJ results_NNS were_VBD obtained_VBN when_WRB the_DT phosphorylation_NN of_IN the_DT S6_NP protein_NN was_VBD examined_VBN as_IN a_DT cellular_JJ read-out_JJ of_IN p70_JJ S6_NP kinase_NN activity_NN ._SENT Phosphorylation_NN of_IN S6_NP in_IN response_NN to_TO PMA_NN was_VBD greater_JJR than_IN in_IN response_NN to_TO alphaCD3_NN and_CC alphaCD28_NN ,_, similarly_RB to_TO the_DT situation_NN for_IN several_JJ translation_NN factors_NNS ,_, as_RB described_VBN above_IN ._SENT Figure_NP 7_CD |_SYM Regulation_NN of_IN p70_JJ S6_NP kinase_NN ._SENT Regulation_NN of_IN p70_JJ S6_NP kinase.A_NN ._SENT Primary_JJ T_NN lymphocytes_NNS were_VBD preincubated_VBN with_IN wortmannin_NP (_( W_NP ,_, 100_CD nM_NN )_) ,_, rapamycin_NP (_( R_NP ,_, 100_CD nM_NN )_) ,_, SB203580_NP (_( SB_NP ,_, 10_CD muM_NN )_) ,_, or_CC PD98059_NP (_( PD_NP ,_, 50_CD muM_NN )_) for_IN 30_CD min_NN before_IN activation_NN with_IN both_DT alphaCD3_NN and_CC alphaCD28_JJ (_( black_JJ bars_NNS )_) for_IN 60_CD min_NN ._SENT Bars_NNS marked_VBD with_IN *_SYM are_VBP significantly_RB different_JJ (_( p<0.01_JJ )_) from_IN the_DT activity_NN in_IN untreated_JJ cells_NNS (_( n=4_NN )_) ._SENT B._NP T_NN cells_NNS were_VBD preincubated_VBN with_IN wortmannin_NP (_( W_NP ,_, 100_CD nM_NN )_) ,_, rapamycin_NP (_( R_NP ,_, 100_CD nM_NN )_) ,_, SB203580_NP (_( SB_NP ,_, 10_CD muM_NN )_) ,_, or_CC PD98059_NP (_( PD_NP ,_, 50_CD muM_NN )_) for_IN 30_CD min_NN before_IN activation_NN with_IN both_DT alphaCD3_NN and_CC alphaCD28_NN for_IN 60_CD min_NN or_CC the_DT cells_NNS were_VBD stimulated_VBN with_IN PMA_NN for_IN 60_CD min_NN ._SENT Phosphorylation_NN of_IN the_DT S6_NP protein_NN was_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG using_VBG a_DT phospho-specific_JJ S6_NP (_( Ser235_NP )_) antibody_NN ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN four_CD experiments_NNS ._SENT The_DT mechanisms_NNS underlying_VBG the_DT regulation_NN of_IN protein_NN synthesis_NN following_VBG activation_NN of_IN resting_VBG primary_JJ T_NN cells_NNS has_VBZ not_RB been_VBN widely_RB studied_VBN ._SENT Early_JJ reports_NNS showed_VBD that_DT stimulation_NN of_IN primary_JJ T_NN cells_NNS with_IN pharmacological_JJ stimuli_NNS ,_, e.g._FW PHA_NP or_CC PMA_NN ,_, led_VBN to_TO an_DT increase_NN in_IN protein_NN synthesis_NN and_CC protein_NN levels_NNS of_IN certain_JJ translation_NN initiation_NN factors_NNS within_IN 16_CD h_NN ._SENT More_RBR recently_RB the_DT regulation_NN of_IN protein_NN synthesis_NN and_CC translation_NN factors_NNS after_IN a_DT 6_CD h_NN stimulation_NN of_IN primary_JJ T_NN cells_NNS with_IN PMA_NN or_CC PMA/ionomycin_NP was_VBD described_VBN in_IN detail_NN ._SENT We_PP investigated_VBD the_DT regulation_NN of_IN protein_NN synthesis_NN and_CC translation_NN factors_NNS during_IN the_DT early_JJ phase_NN of_IN activation_NN of_IN resting_VBG T_NN cells_NNS by_IN alphaCD3_NN and_CC alphaCD28_NN ,_, i.e._FW 1_CD h_NN of_IN activation_NN ._SENT The_DT protein_NN synthesis_NN rate_NN in_IN T_NN cells_NNS rapidly_RB increased_VBN after_IN treatment_NN ,_, and_CC several_JJ signalling_VBG pathways_NNS ,_, i.e._FW ERK_NP and_CC p38_NP MAPK_NP phosphorylation_NN and_CC PKB_NN activation_NN ,_, were_VBD stimulated_VBN ,_, showing_VBG the_DT efficacy_NN of_IN the_DT alphaCD3_NN and_CC alphaCD28_NN antibodies_NNS in_IN activating_VBG the_DT cells_NNS ._SENT The_DT increase_NN in_IN protein_NN synthesis_NN after_IN 1_CD h_NN was_VBD mediated_VBN via_IN multiple_JJ signalling_VBG pathways_NNS ,_, e.g._FW the_DT MEK_NP ,_, p38_NP MAPKalpha/beta_NP ,_, PI_NP 3-kinase_NN and_CC mTOR_NN pathway_NN ,_, as_RB indicated_VBN by_IN the_DT use_NN of_IN signal_NN transduction_NN inhibitors_NNS ._SENT In_IN several_JJ cell_NN types_NNS ,_, the_DT involvement_NN of_IN either_DT MEK_NP ,_, PI_NP 3-kinase_NP or_CC mTOR_NNS [_SYM ,,-_NN ]_SYM in_IN the_DT activation_NN of_IN protein_NN synthesis_NN has_VBZ been_VBN described_VBN ._SENT However_RB ,_, this_DT is_VBZ the_DT first_JJ time_NN that_IN a_DT role_NN for_IN the_DT p38_JJ MAPKalpha/betapathway_NN in_IN the_DT regulation_NN of_IN overall_JJ protein_NN synthesis_NN has_VBZ been_VBN described_VBN ._SENT This_DT role_NN is_VBZ supported_VBN by_IN the_DT fact_NN that_IN two_CD structurally_RB unrelated_JJ p38_JJ MAPKalpha/beta_NP inhibitors_NNS ,_, i.e._FW ,_, SB202190_NP and_CC SB203580_NP ,_, were_VBD each_DT able_JJ to_TO block_VB the_DT increase_NN in_IN protein_NN synthesis_NN ._SENT The_DT increase_NN in_IN protein_NN synthesis_NN after_IN activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN coincided_VBN with_IN an_DT increase_NN in_IN the_DT activities_NNS of_IN p70_JJ S6_NP kinase_NN and_CC eIF2B_NN and_CC dephosphorylation_NN of_IN eEF2_NN ,_, which_WDT is_VBZ indicative_JJ of_IN an_DT increase_NN in_IN its_PP$ activity_NN ._SENT The_DT dephosphorylation_NN of_IN eEF2_NN was_VBD very_RB transient_JJ ,_, and_CC therefore_RB it_PP is_VBZ unlikely_JJ that_IN eEF2_NN plays_VBZ an_DT important_JJ role_NN in_IN the_DT sustained_JJ increase_NN in_IN protein_NN synthesis_NN after_IN T_NN cell_NN activation_NN ._SENT However_RB ,_, activation_NN of_IN eEF2_NN could_MD be_VB important_JJ for_IN the_DT initial_JJ increase_NN in_IN protein_NN synthesis_NN ._SENT The_DT stimulation_NN of_IN p70_JJ S6_NP kinase_NN was_VBD mediated_VBN via_IN similar_JJ signalling_VBG pathways_NNS (_( Fig._NN 7_CD )_) to_TO those_DT underlying_VBG the_DT activation_NN of_IN overall_JJ protein_NN synthesis_NN ._SENT Inhibition_NN of_IN PI_NP 3-kinase_NP ,_, mTOR_NN ,_, p38_NP MAPKalpha/beta_NP ,_, or_CC MEK_NP during_IN T_NN cell_NN activation_NN by_IN alphaCD3_NN and_CC alphaCD28_NN prevented_VBD the_DT activation_NN of_IN p70_JJ S6_NP kinase_NN ,_, indicating_VBG that_IN multiple_JJ signalling_VBG pathways_NNS are_VBP required_VBN for_IN regulation_NN of_IN p70_JJ S6_NP kinase_NN activity_NN ._SENT The_DT effect_NN of_IN rapamycin_NN on_IN the_DT activation_NN of_IN p70_JJ S6_NP kinase_NN in_IN response_NN to_TO alphaCD3_NN and_CC alphaCD28_NN has_VBZ been_VBN reported_VBN previously_RB ._SENT Inhibition_NN of_IN the_DT activation_NN of_IN p70_JJ S6_NP kinase_NN by_IN SB203580_NP has_VBZ been_VBN described_VBN before_IN in_IN insulin-stimulated_JJ rat_NN vascular_JJ smooth_JJ muscle_NN cells_NNS [_SYM ,-_NN ]_SYM ._SENT Furthermore_RB ,_, it_PP has_VBZ been_VBN reported_VBN that_WDT SB203580_NN (_( at_IN the_DT concentration_NN used_VBD ,_, 10_CD muM_NN )_) can_MD inhibit_VB phosphorylation_NN of_IN PKB_NP at_IN Threonine308_NP and_CC thus_RB its_PP$ activation_NN ._SENT Since_IN PKB_NP is_VBZ an_DT upstream_JJ component_NN of_IN the_DT signalling_VBG pathway_NN towards_IN p70_JJ S6_NP kinase_NN ,_, this_DT could_MD provide_VB a_DT mechanism_NN by_IN which_WDT SB203580_NP blocks_VBZ activation_NN of_IN p70_JJ S6_NP kinase_NN ._SENT Each_DT of_IN the_DT other_JJ signalling_VBG pathways_NNS studied_VBN here_RB has_VBZ also_RB been_VBN implicated_VBN in_IN the_DT regulation_NN of_IN p70_JJ S6_NP kinase_NN activity_NN in_IN a_DT variety_NN of_IN cell_NN types_NNS under_IN a_DT range_NN of_IN conditions_NNS [_SYM ,-_NN ]_SYM ._SENT However_RB ,_, in_IN human_JJ primary_JJ T_NN cells_NNS all_RB of_IN them_PP appear_VBP to_TO be_VB important_JJ for_IN the_DT regulation_NN of_IN p70_JJ S6_NP kinase_NN activity_NN after_IN stimulation_NN with_IN alphaCD3_NN and_CC alphaCD28_NN ._SENT The_DT activity_NN of_IN the_DT guanine_NN nucleotide_NN exchange_NN factor_NN ,_, eIF2B_NN ,_, also_RB was_VBD mediated_VBN via_IN similar_JJ signalling_VBG pathways_NNS as_IN the_DT increase_NN in_IN protein_NN synthesis_NN ._SENT The_DT increase_NN in_IN eIF2B_NN activity_NN after_IN activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN ,_, at_IN the_DT early_JJ times_NNS we_PP examined_VBD ,_, was_VBD not_RB due_JJ to_TO an_DT increase_NN in_IN eIF2B_NN protein_NN level_NN or_CC to_TO changes_NNS in_IN eIF2alpha_NN phosphorylation_NN ._SENT Therefore_RB ,_, modification_NN of_IN the_DT eIF2B_NN protein_NN complex_NN probably_RB caused_VBD the_DT increase_NN in_IN eIF2B_NN activity_NN ._SENT The_DT modulation_NN of_IN the_DT activity_NN of_IN the_DT eIF2B_NN complex_NN after_IN activation_NN of_IN T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN required_VBN several_JJ different_JJ signalling_VBG pathways_NNS ,_, e.g._FW MEK_NP ,_, p38_NP MAPKalpha/beta_NP ,_, mTOR_NN and_CC the_DT PI_NP 3-kinase_NN pathway_NN ._SENT These_DT signalling_VBG pathways_NNS have_VBP been_VBN reported_VBN separately_RB to_TO be_VB involved_VBN in_IN the_DT regulation_NN of_IN eIF2B_NN activity_NN ._SENT However_RB ,_, this_DT is_VBZ the_DT first_JJ report_NN where_WRB all_PDT these_DT pathways_NNS are_VBP involved_VBN in_IN the_DT regulation_NN of_IN eIF2B_NN in_IN a_DT single_JJ cell_NN type_NN ._SENT A_DT small_JJ inactivation_NN of_IN GSK-3_NP was_VBD detected_VBN after_IN activation_NN of_IN primary_JJ T_NN cells_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN ._SENT However_RB ,_, no_DT dephosphorylation_NN of_IN Ser540_NP in_IN eIF2Bepsilon_NP was_VBD detected_VBN ,_, excluding_VBG a_DT role_NN for_IN GSK-3_NP in_IN regulating_VBG the_DT activity_NN of_IN eIF2B_NN under_IN these_DT conditions_NNS ._SENT In_IN contrast_NN ,_, studies_NNS employing_VBG PMA/ionomycin-activated_JJ T_NN cells_NNS ,_, insulin_NN treatment_NN of_IN various_JJ cell_NN types_NNS ,_, and_CC cell_NN survival_NN have_VBP implied_VBN a_DT role_NN for_IN GSK-3_NP in_IN regulating_VBG eIF2B_NN activity_NN ._SENT In_IN contrast_NN to_TO previously_RB reported_VBN data_NNS using_VBG mitogenic_JJ stimuli_NNS to_TO activate_VB primary_JJ T_NN cells_NNS or_CC Jurkat_NP T_NN cells_NNS ,_, eIF4E_JJ phosphorylation_NN ,_, association_NN of_IN eIF4G_NN with_IN eIF4E_NNS and_CC 4E-BP1_JJ phosphorylation_NN remained_VBD unchanged_JJ after_IN T_NN cell_NN activation_NN using_VBG alphaCD3_NN and_CC alphaCD28_NN as_IN a_DT stimulus_NN ._SENT Signal_NN transduction_NN inhibitor_NN studies_NNS showed_VBD that_IN the_DT MEK_NP and_CC p38_NP MAPKalpha/beta_NP pathways_NNS are_VBP important_JJ for_IN eIF4E_JJ phosphorylation_NN in_IN Jurkat_NP T_NN cells_NNS ,_, and_CC a_DT role_NN for_IN MEK_NP was_VBD demonstrated_VBN previously_RB in_IN primary_JJ T_NN cells_NNS ._SENT The_DT weaker_JJR activation_NN of_IN the_DT ERK_NP pathway_NN in_IN particular_JJ by_IN alphaCD3_NN and_CC alphaCD28_NN in_IN primary_JJ T_NN cells_NNS may_MD well_RB account_VB for_IN the_DT absence_NN of_IN increased_VBN phosphorylation_NN of_IN eIF4E_NNS under_IN these_DT conditions_NNS ._SENT We_PP did_VBD not_RB observe_VB increased_VBN phosphorylation_NN of_IN 4E-BP1_JJ in_IN response_NN to_TO alphaCD3_NN and_CC alphaCD28_NN ,_, even_RB though_IN it_PP has_VBZ been_VBN reported_VBN to_TO occur_VB after_IN cytokine_NN stimulation_NN of_IN a_DT murine_JJ cytotoxic_JJ T_NN cell_NN line_NN or_CC after_IN 6_CD h_NN of_IN mitogenic_JJ stimulation_NN of_IN human_JJ primary_JJ T_NN cells_NNS ._SENT However_RB ,_, Grolleau_NP et_FW al._FW showed_VBD that_DT 4E-BP1_JJ was_VBD present_JJ in_IN primary_JJ T_NN cells_NNS mainly_RB in_IN its_PP$ dephosphorylated_JJ form_NN ,_, and_CC no_DT significant_JJ change_NN was_VBD detected_VBN after_IN PMA_NN treatment_NN ._SENT Our_PP$ results_NNS are_VBP consistent_JJ with_IN this_DT last_JJ finding_NN ;_: 4E-BP1_JJ is_VBZ mainly_RB present_JJ as_IN one_CD band_NN ,_, and_CC no_DT change_NN in_IN mobility_NN is_VBZ observed_VBN upon_IN cell_NN treatment_NN ._SENT This_DT is_VBZ consistent_JJ with_IN the_DT observation_NN that_IN eIF4F_NN complex_JJ formation_NN did_VBD not_RB alter_VB ._SENT However_RB ,_, it_PP remains_VBZ surprising_JJ that_IN eIF4F_NN complexes_NNS are_VBP present_JJ when_WRB 4E-BP1_JJ is_VBZ completely_RB dephosphorylated_JJ ,_, and_CC therefore_RB presumably_RB associated_VBN with_IN eIF4E_NNS ._SENT We_PP were_VBD unable_JJ to_TO detect_VB any_DT 4E-BP1_JJ associated_VBN with_IN eIF4E_NN ,_, which_WDT is_VBZ probably_RB due_JJ to_TO the_DT low_JJ 4E-BP1_JJ protein_NN levels_NNS in_IN resting_JJ T_NN lymphocytes_NNS ,_, thus_RB explaining_VBG basal_JJ eIF4F_NN formation_NN ._SENT The_DT treatment_NN of_IN primary_JJ T_NN lymphocytes_NNS with_IN alphaCD3_NN and_CC alphaCD28_NN activates_VBZ two_CD key_JJ components_NNS of_IN the_DT translational_JJ machinery_NN ,_, p70_JJ S6_NP kinase_NN and_CC eIF2B_NN ._SENT The_DT activities_NNS of_IN these_DT translation_NN factors_NNS were_VBD regulated_VBN similarly_RB to_TO the_DT activation_NN of_IN protein_NN synthesis_NN ,_, consistent_JJ with_IN an_DT important_JJ role_NN for_IN the_DT components_NNS in_IN the_DT activation_NN of_IN protein_NN synthesis_NN by_IN alphaCD3_NN and_CC alphaCD28_NN ._SENT Interestingly_RB ,_, activation_NN of_IN protein_NN synthesis_NN ,_, p70_JJ S6_NP kinase_NN ,_, and_CC eIF2B_NN is_VBZ inhibited_VBN by_IN rapamycin_NN ,_, a_DT compound_NN that_WDT was_VBD first_RB discovered_VBN as_IN an_DT immunosuppressant_NN ,_, suggesting_VBG that_IN mTOR_NN regulated_JJ translation_NN is_VBZ involved_VBN in_IN the_DT process_NN of_IN T_NN cell_NN proliferation_NN ._SENT The_DT activation_NN of_IN p70_JJ S6_NP kinase_NN is_VBZ related_VBN to_TO the_DT regulation_NN of_IN translation_NN of_IN specific_JJ mRNAs_NNS ,_, while_IN the_DT activation_NN of_IN eIF2B_NN is_VBZ likely_JJ to_TO be_VB required_VBN for_IN stimulation_NN of_IN general_JJ protein_NN synthesis_NN ._SENT This_DT suggests_VBZ that_IN increases_NNS in_IN both_DT specific_JJ and_CC general_JJ protein_NN synthesis_NN are_VBP important_JJ in_IN the_DT early_JJ phase_NN of_IN T_NN cell_NN activation_NN ._SENT Primary_JJ T_NN cell_NN isolation_NN and_CC cell_NN treatment_NN |_SYM Buffy_JJ coats_NNS used_VBN for_IN the_DT isolation_NN of_IN T_NN cells_NNS were_VBD prepared_VBN from_IN freshly_RB drawn_VBN blood_NN from_IN healthy_JJ human_JJ donors_NNS and_CC were_VBD obtained_VBN from_IN the_DT Scottish_NP National_NP Blood_NP Transfusion_NP Service_NP (_( Edinburgh_NP ,_, UK_NP )_) ._SENT Mononuclear_JJ leukocytes_NNS were_VBD isolated_VBN by_IN Ficoll-Hypaque_NP (_( Amersham-Pharmacia_NP )_) gradient_JJ centrifugation_NN ._SENT T_NN cells_NNS were_VBD further_RBR enriched_VBN using_VBG nylon-wool_NN columns_NNS ._SENT T_NN cells_NNS were_VBD suspended_VBN in_IN RPMI_NP 1640_CD medium_NN supplemented_VBN with_IN 10_CD %_NN (_( v/v_NP )_) heat-inactivated_VBD foetal_JJ calf_NN serum_NN ,_, 1_CD mM_NP glutamine_NN and_CC antibiotics/antimycotics_NN 